Averin Capital Launches $250M SPAC to Hunt for HealthTech Innovators

NEW YORK, NY – February 20, 2026 – Averin Capital Acquisition Corp., a newly formed special purpose acquisition company (SPAC), today announced the successful closing of its $250 million initial public offering, signaling the arrival of a formidable new player focused on the burgeoning health technology sector. The company’s units began trading on the Nasdaq Global Stock Market on February 19 under the ticker symbol “ACAAU.”

The offering, priced at $10.00 per unit, provides the blank check company with a substantial war chest to pursue a merger or acquisition. Each unit consists of one Class A ordinary share and one-sixth of a redeemable warrant, with a whole warrant exercisable at $11.50 per share. This successful capital raise, managed by sole book-runner Deutsche Bank Securities Inc., positions Averin Capital to identify and merge with a private company, thereby taking it public.

A Disciplined Entry into a Resurgent Market

Averin Capital’s debut comes as the SPAC market is experiencing a period of “cautious optimism” and disciplined growth. After a turbulent period, the market saw a significant rebound in 2025, with the number of new SPAC IPOs roughly doubling from the previous year. This resurgence is taking place under a more rigorous regulatory framework established by the SEC in 2024, which demands greater transparency and aligns SPACs more closely with traditional IPO standards.

This new environment favors experienced sponsors with clear, sector-specific strategies—a mold that Averin Capital fits perfectly. In 2025, nearly 80% of SPAC IPOs were launched by serial sponsors, indicating a market shift toward professional, institutional-grade management. While redemption rates for SPACs remain high across the industry, investors are increasingly betting on leadership teams with proven track records to navigate the complexities of identifying a valuable target and successfully closing a deal.

Averin Capital’s $250 million raise is in line with the trend of larger, more substantial SPACs that are better positioned to acquire mature, high-growth companies. With its capital secured in a trust account, the company now begins its two-year window to find a suitable partner at the dynamic intersection of technology and healthcare.

A Powerhouse Leadership Team

At the heart of investor confidence in Averin Capital is its distinguished leadership, helmed by Chairman and CEO Dr. David A. Berry. A prolific entrepreneur and innovator, Dr. Berry brings a formidable track record from his two decades as a General Partner at Flagship Pioneering, a life sciences venture capital firm. During his tenure, he co-founded over 30 companies, seven of which achieved “unicorn” status with valuations exceeding $1 billion.

Dr. Berry’s experience is deeply rooted in the very sectors Averin Capital intends to target. He was the founding CEO of Valo Health, a company leveraging human-centric data and AI-powered computation to revolutionize drug discovery, which raised over $500 million and secured a major partnership with Novo Nordisk. He also played foundational roles at companies like Evelo Biosciences, Seres Health, and Omega Therapeutics, demonstrating a unique ability to shepherd scientific concepts from the lab to commercial success. His credentials, which include an M.D. from Harvard Medical School and a Ph.D. in biological engineering from MIT, lend significant scientific and business credibility to the SPAC’s mission.

He is joined by Chief Financial Officer Alex Lau and a board that includes industry veterans Ulrik Schulze, Graeme Bell, and Mary T. Szela. This combination of scientific acumen, entrepreneurial success, and public market experience is designed to give Averin Capital a distinct advantage in sourcing and executing a high-value transaction.

Targeting a Sector Ripe for Disruption

Averin Capital has set its sights on the intersection of technology and health, a sector experiencing explosive growth and transformation. The U.S. digital health market alone is projected to swell to $580 billion by 2030, fueled by relentless innovation and the urgent need for more efficient and effective healthcare solutions. Global investment in the space is robust, with digital health startups attracting nearly $29 billion in funding in 2025.

Artificial intelligence is a key driver of this transformation and a central focus of M&A activity. AI is expected to unlock up to $150 billion in annual cost savings for the U.S. healthcare system by 2026, creating immense value for companies that can successfully implement it. Averin Capital is likely to target businesses leveraging AI for diagnostics, remote patient monitoring, personalized medicine, and revenue cycle management.

Other high-potential areas include digital therapeutics, next-generation wearable devices, and platforms that enhance data interoperability to create a more connected healthcare ecosystem. After a brief cooling-off period, health services M&A is poised for a rebound in 2026, with private equity and strategic acquirers like Averin Capital ready to deploy capital into companies that are moving beyond experimentation and building the core infrastructure of modern healthcare.

With its public listing complete and capital secured, Averin Capital now begins the critical search for a transformative business to bring to the public markets. The market will be watching closely to see which innovator this well-funded, expert-led SPAC chooses as its partner to shape the future of health and technology.